Type
Sandwich ELISA, Biotin-labelled antibody
Applications
Tissue homogenates, Serum, Urine, Cerebrospinal fluid, Amniotic fluid, Plasma
Storage/Expiration
Store the complete kit at 2 8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Calibration Curve
Calibration Range
0.63 – 40 ng/ml
Limit of Detection
58 pg/ml
Intra-assay (Within-Run)
n = 8; CV = 4.8%
Inter-assay (Run-to-Run)
n = 6; CV = 4.9%
Spiking Recovery
92.6%
Dilutation Linearity
99.5%
Features
- The total assay time is less than 3.5 hours
- The kit measures IGFBP-7 in human serum, plasma (EDTA, citrate, heparin), urine, cerebrospinal fluid, amniotic fluid and tissue homogenates
- Assay format is 96 wells
- Standard is recombinant protein based
- Components of the kit are provided ready to use, concentrated or lyophilized
Research topic
Apoptosis, Diabetology - Other Relevant Products, Oncology, Renal disease
Summary
Insulin-like growth factor binding protein 7 (IGFBP7), also known as mac25 or IGFBP-related protein-1 (IGFBP-rP1), is a secreted protein belonging to the insulin-like growth factor (IGF) system. The IGF axis plays a key role in normal growth and development, and in pathophysiology of various cancers in mammals.
IGFBP7 is expressed in a variety of normal tissues including heart, spleen, ovary, small intestine and colon and has been found in biological fluids, such as serum, urine, CSF and amniotic fluid. While normal tissues express IGFBP7 abundantly, no or very weak IGFBP7 expression is detected in many cancers. Its expression is lost upon progression to more aggressive cancer types and loss of IGFBP7 expression is associated with poor prognosis. , IGFBP7 has been shown to be a tumor suppressor for solid cancer such as breast, colorectal, hepatocellular, prostate and thyroid cancer, melanoma and glioma. Reexpression of IGFBP7 or exposure of cancer cell lines to IGFBP7 results in either senescence or apoptosis. Overexpression of IGFBP7 significantly inhibited growth of cancer cells both in vitro and in vivo, thus, IGFBP7 could be a novel therapeutic target in cancer therapy.
In addition it was discovered, that IGFBP7 and tissue inhibitor of metalloproteinases-2 (TIMP-2) are two novel biomarkers for identification of moderate to severe acute kidney injury (AKI) in critically ill patients.
